Cited by 84Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerDrug Transport and Resistance Mechanisms

Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids

Sansome, Daniel J., Xie, Cong, Veedfald, Simon, Horowitz, Michael, Rayner, Christopher K., Wu, Tongzhi·2020·Diabetes, Obesity and Metabolism

Abstract

Type 2 diabetes mellitus (T2DM) is an increasingly prevalent chronic condition, characterized by abnormally elevated blood glucose concentrations and, as a consequence, increased risk of micro- and macrovascular complications. Metformin is usually the first-line glucose-lowering medication in T2DM; however, despite being used for more than 60 years, the mechanism underlying the glucose-lowering action of metformin remains incompletely understood. Although metformin reduces hepatic glucose production, there is persuasive evidence that the gastrointestinal tract is crucial in mediating this effect, particularly via secretion of the incretin hormone glucagon-like peptide 1 (GLP-1). It is now well recognized that bile acids, in addition to their established function in fat digestion and absorption, are important regulators of glucose metabolism. Exposure of the small and large intestine to bile acids induces GLP-1 secretion, modulates the composition of the gut microbiota, and reduces postprandial blood glucose excursions in humans with and without T2DM. Metformin reduces intestinal bile acid resorption substantially, such that intraluminal bile acids may, at least in part, account for its glucose-lowering effect. The present review focuses on the conceptual shift in our understanding as to how metformin lowers blood glucose in T2DM, with a particular emphasis on the role of intestinal bile acids.

Integrity signals

Registry

Crossref · 10.1111/dom.13869

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T.
Affiliations
  • The University of Adelaide (AU)
  • University of Copenhagen (DK)
  • Zhongda Hospital Southeast University (CN)
Corresponding author
Wu, Tongzhi
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-10-07
Volume
22
Issue
2
Pages
141-148
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2970301864
Cited by
84
References
9
Citations by year
2026: 6 · 2025: 10 · 2024: 14 · 2023: 19 · 2022: 9 · 2021: 15 · 2020: 11
FWCI
1.54
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Obesity and Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Funders
  • Diabetes Australia Research Trust (Y19G‐WUTO)
  • National Health and Medical Research Council (APP1147333)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
metformin, type 2 diabetes, glucose-lowering mechanism, bile acids, glucagon-like peptide-1, incretin secretion, gut microbiota, postprandial blood glucose, hepatic glucose production, gastrointestinal tract
MeSH terms
Bile Acids and Salts, Blood Glucose, Diabetes Mellitus, Type 2, Glucose, Humans, Intestinal Mucosa, Intestines, Metformin, Carbohydrate Metabolism, Metabolic Networks and Pathways

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review